Loading...
XNAS
PBLA
Market cap1mUSD
Jun 16, Last price  
0.24USD
1D
-20.00%
1Q
-38.46%
IPO
-100.00%
Name

Panbela Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
180.33%
Rev. gr., 5y
%
Revenues
0k
699,7551,232,704973,8131,356,995000000000
Net income
-25m
L-27.68%
-138,313247,380-212,021-107,044-4,927,000-5,112,000-10,374,000-5,905,000-6,200,000-4,768,000-10,135,000-34,933,000-25,263,000
CFO
-25m
L+65.29%
-73,04137,113-35,390-11,453-3,897,000-2,398,000-3,402,000-2,387,000-2,739,000-3,854,000-6,704,000-15,276,000-25,249,000
Earnings
Aug 11, 2025

Profile

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
IPO date
Jul 29, 2014
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
51,294
69,824
Unusual Expense (Income)
NOPBT
(51,294)
(69,824)
NOPBT Margin
Operating Taxes
(186)
(116)
Tax Rate
NOPAT
(51,108)
(69,708)
Net income
(25,263)
-27.68%
(34,933)
244.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,053
5,349
BB yield
Debt
Debt current
1,000
1,650
Long-term debt
4,194
5,194
Deferred revenue
Other long-term liabilities
Net debt
2,616
5,559
Cash flow
Cash from operating activities
(25,249)
(15,276)
CAPEX
(660)
Cash from investing activities
400
(656)
Cash from financing activities
26,142
5,354
FCF
(47,256)
(65,302)
Balance
Cash
2,578
1,285
Long term investments
Excess cash
2,578
1,285
Stockholders' equity
(124,752)
(90,334)
Invested Capital
125,236
89,129
ROIC
ROCE
5,794.52%
EV
Common stock shares outstanding
Price
18.30
-98.96%
1,759.20
-95.76%
Market cap
EV
EBITDA
(51,294)
(69,824)
EV/EBITDA
Interest
317
288
Interest/NOPBT